St. Jude Children’s Research Hospital is a National Cancer Institute (NCI)–designated Comprehensive Cancer Center devoted solely to children. Our 300 faculty work across the spectrum of basic, translational, clinical, and population science in a highly collaborative multidisciplinary environment that includes a Nobel laureate and members of the National Academy of Science and the National Academy of Medicine. St. Jude is ranked on Fortune Magazine’s “Best Workplaces in Health Care & Biopharma” and Glassdoor’s “Best Places to Work,” and is located in the heart of Memphis, Tennessee, a vibrant and friendly city at the historic American crossroads of music, trade, food and culture. At St. Jude, we have one common goal: find cures for children with cancer and other life-threatening diseases through research and treatment. As both a world-class research institute and a specialized children’s hospital, St. Jude provides an unparalleled opportunity to advance your scientific training and launch your career. | St. Jude Children’s Research Hospital is a global leader in the research and treatment of pediatric cancer and other life-threatening diseases of childhood. Headquartered in Memphis, Tennessee, St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude has been named a top pediatric cancer hospital on U.S. News & World Report’s annual “Best Hospitals” list and named to Fortune magazine’s “100 Best Companies to Work For” list. Research and treatments developed at St. Jude are shared to help improve the survival rate for children with cancer and other life-threatening diseases worldwide. St. Jude is recognized as one of the world’s premier pediatric research and treatment institutions with a focus on acute lymphoblastic leukemia, brain tumors and infectious diseases. With eight affiliate clinics across the country, St. Jude treats about 8,600 children each year. Beyond the United States, the institution’s St. Jude Global initiative seeks to improve health care for children with life-threatening disease worldwide. The goal of the Department of Infectious Diseases at St. Jude Children’s Research Hospital is to study devastating diseases of childhood through a comprehensive approach including basic science research, translational trials, and bedside care. Among the top infectious causes of death worldwide are respiratory diseases and HIV/AIDS. The Department of Infectious Diseases seeks to focus on the pathogenesis of these infections with a breadth of commitment that extends from the research bench to the bedside. Investigations take place at progressive levels: manipulation of genes is expected to lead to phenotypes in cell culture systems that can be modeled in animal studies. Therapeutic candidates in the form of antimicrobials, vaccines, or adjunctive therapies are further pursued in clinical trials in children. Follow us to discover the research, scientific discoveries, clinical care and employment opportunities at St. Jude. View our career opportunities: www.stjude.org/JoinOurMission. Follow St. Jude across social media at @stjuderesearch.
SeqDiagnostics
SeqDiagnostics is a molecular diagnostics company developing next-generation sequencing (NGS) assays to improve the detection and characterization of respiratory infections. Our flagship assay, NTM-Seq, provides rapid species-level identification and antimicrobial resistance insights for nontuberculous mycobacteria directly from respiratory samples, helping clinicians make more informed treatment decisions.
Sanford Guide
Since 1969, Sanford Guide has been the leading clinical treatment guide for infectious diseases. Offering proven solutions for individual clinicians and antimicrobial stewardship programs worldwide.
QuidelOrtho
QuidelOrtho develops and manufactures intelligent solutions that are transforming the power of diagnostics into a healthier future for all, helping spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence. Together, we are transforming the power of diagnostics into a healthier future for all. | QuidelOrtho MicroVue Complement system products are a well-established name in immune system monitoring, providing a variety of first-in-class diagnostic and research solutions. The SPG product portfolio includes ELISA assays, multiplex, antibodies, proteins and sera-based products such as depleted sera, normal human serum and cobra venom factor.
Q-linea
At Q-linea, we design, develop, and deliver innovative infectious diseases diagnostic technology to improve patient outcomes and save lives. Our leading product, ASTar®, is a fully automated rapid AST system, direct from positive blood cultures. ASTar® produces results within approximately six hours and aims to reduce time to optimal therapy.
Paratek Pharmaceuticals
Paratek Pharmaceuticals is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are difficult to treat. At Paratek, we pursue solutions that enable positive outcomes and lead to positive patient stories.
Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com. | Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com. Invitae is a part of Labcorp. | We are a global life sciences and healthcare company harnessing science for human good. Every day, our mission is to improve health and improve lives. | Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at https://www.labcorp.com/infectious-disease.
CorMedix Therapeutics
Melinta Therapeutics provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes seven commercial-stage products. With an unsurpassed commitment to providers and the patients they serve, we work to ensure that all people who need our therapies can receive them. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Visit www.melinta.com for more information. | At CorMedix Therapeutics, we’re driven to protect vulnerable patients from serious, life-threatening infections. With eight commercial-stage products spanning prevention and treatment, we address critical, unmet needs across multiple care settings. Our dedicated team is committed to ensuring access to our therapies and to continuously expanding our portfolio to improve patient outcomes. Discover more at www.cormedix.com
Clarametyx Biosciences
Clarametyx Biosciences is combating the formidable challenge of chronic respiratory diseases through an innovative technology platform targeting bacterial biofilms. The Columbus, Ohio-based company is building a pipeline of immune-enabling medicines, including CMTX-101, which completed a positive Phase 2 study in cystic fibrosis patients in early 2026, and plans to pursue additional mid-stage studies in other chronic respiratory diseases including bronchiectasis. The company’s second program, CMTX-301, is in early development to evaluate the technology in a preventive approach. | Clarametyx Biosciences is combating the formidable challenge of chronic, recalcitrant respiratory disease decline through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines, including CMTX-101, which is in a Phase 2a study for infections associated with cystic fibrosis, and CMTX-301, an anti-biofilm vaccine in early development.